<DOC>
	<DOCNO>NCT02414984</DOCNO>
	<brief_summary>The purpose study describe adherence golimumab Colombian participant rheumatoid arthritis ( RA ) experience adequate treatment response , real-world clinical setting .</brief_summary>
	<brief_title>Registry Analysis Compliance Colombian Participants With Rheumatoid Arthritis Exposed Golimumab</brief_title>
	<detailed_description>This multi-center ( one hospital medical school team work medical research study ) , non-interventional , prospective cohort study enroll participant RA Colombia , treat physician decide treat golimumab prior enrolment . All participant observe adherence golimumab treatment 24 month study start ( Week 0 ) , recommend follow assessment every 3 month . Any change include addition new medication dose modification exist medication entirely accord treat physician 's judgment . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants moderate severe RA physician decide treat golimumab accord local product label , first dose administered 12 26 week prior study enrollment Participants achieve adequate therapeutic response regular dos golimumab , within 12 26 week treatment Participants evaluate tuberculosis ( TB ) exposure/risk factor manage active latent TB ( per local requirement accord local product label ) Participants evaluate active/latent hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Participants , since golimumab initiation , complete medical record available Exclusion criterion : Participants receive terminated golimumab treatment past Participants treat golimumab 26 week prior enrolment study Participants use investigational agent less equal 30 day start treatment golimumab Participants suspect latent TB , receive prophylactic treatment least 4 week Participants suspect active TB Participants active/latent HBV HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Golimumab</keyword>
	<keyword>Observational</keyword>
	<keyword>Compliance</keyword>
</DOC>